Last updated: July 27, 2026
Executive summary: QUVIVIQ (daridorexant) is established as a branded orexin receptor antagonist for insomnia, with ongoing evidence-building studies around efficacy durability, comorbid populations, and formulation/dosing optimizations. Commercial outlook remains tied to label expansion, payer contracting, and share shifts versus competing insomnia agents and orexin rivals. The next material market swing typically comes from (1) trial readouts that broaden use beyond baseline insomnia populations and (2) competitive intensity as generics for older sedatives progress and as other orexin and non-orexin therapies deepen distribution.
What is QUVIVIQ (daridorexant) and what is its current FDA status?
QUVIVIQ is daridorexant, an orexin receptor antagonist developed for insomnia. The FDA reviewed the product under its insomnia indication and granted approvals that support use for sleep onset and/or sleep maintenance depending on labeling details and evidence.
What label claims does daridorexant currently support?
Key label dimensions to track for market sizing:
- Indication scope (sleep onset vs sleep maintenance vs both components).
- Adult-only vs any geriatric emphasis (common in insomnia).
- Dosing guidance (timing relative to bedtime).
- Warnings limiting use in certain patient groups (CYP interactions, impairment, next-day impairment risk).
What regulatory milestones and review history matter for forecasting?
Market projections are most sensitive to:
- Whether FDA expands indications for additional insomnia subtypes or longer-term use.
- Whether FDA updates dosing recommendations based on safety signals or drug-drug interaction findings.
- Whether FDA imposes new REMS-like restrictions or labeling constraints that affect prescribing patterns.
How do ongoing and recent clinical trials for QUVIVIQ change the competitive position?
Clinical-trial readouts for daridorexant typically influence three commercial levers: efficacy breadth, tolerability, and prescriber confidence in special populations. Those levers then determine formulary placement and retention.
Which clinical trial themes drive near-term commercial impact?
- Durability and long-term safety: insomnia is chronic, so real-world persistence depends on long-term tolerability and sustained efficacy.
- Patient subgroups: older adults, those with comorbid depression/anxiety, and those using polypharmacy can widen the addressable population.
- Sleep phenotypes: trials that distinguish sleep onset latency from wake after sleep onset or total sleep time tend to clarify differentiation.
- Drug-drug interaction and CNS safety: orexin antagonists face scrutiny around next-day impairment and interactions with CNS depressants and CYP pathways.
What endpoints are most relevant to FDA and payer decisions?
Forecasting trial impact requires focusing on:
- Change from baseline in wake after sleep onset (WASO) and sleep onset latency (SOL).
- Clinical responder analyses (often defined by threshold improvement).
- Next-morning impairment proxies and residual sedative effects.
- Discontinuation rates and TEAE discontinuations.
What clinical trials readouts for daridorexant are most important for 2026 to 2028 projections?
A practical projection framework ties the timeline of readouts to formulary and purchasing cycle dates.
Timing model for how trial results translate into sales
- Quarter 0 to 2 after readout: clinician education, payer evidence packets, and PBM value assessment begins.
- Quarter 2 to 4: formulary committees decide tier placement; prior authorizations and quantity limits may tighten or loosen.
- 12 to 24 months: market share reflects contract outcomes, channel mix, and switching behavior.
What “evidence categories” most move uptake?
- New data that allow “patient fit” expansion (e.g., older adults, comorbidities).
- Comparative or indirect comparisons that strengthen the benefit-risk profile versus competing insomnia drugs.
- Real-world style endpoints (or high quality safety durability datasets) that reduce discontinuation fears.
How does QUVIVIQ (daridorexant) compare with other insomnia treatments on efficacy and tolerability?
Market share depends on how payers and prescribers differentiate daridorexant against:
- Other orexin antagonists (class competition).
- Z-drugs (historical backbone with safety concerns).
- Benzodiazepines and “benzodiazepine-like” agents (residual sedative and dependence risks).
- Melatonin receptor agonists and antidepressant off-label options.
What differentiates orexin antagonists in payer and physician decision-making?
- Lower risk of tolerance and dependence compared with traditional sedatives (as reflected in clinical and postmarketing discussions).
- Different safety profile around next-day impairment and residual CNS effects than Z-drugs in many patients.
- Prescriber acceptance of targeted mechanism vs broad CNS depressants.
How does the class competition risk QUVIVIQ forecasts?
- If another orexin competitor demonstrates stronger efficacy in a specific insomnia component, it can pull share even with similar class safety.
- If another agent secures better payer placement, QUVIVIQ adoption may plateau even if clinical performance is comparable.
When does QUVIVIQ face patent and exclusivity expiration risk?
Sales projections for branded insomnia drugs depend on both patent term and any exclusivity extensions tied to new indications or formulations.
What protections typically matter for insomnia drug revenue?
- Composition of matter patents on daridorexant.
- Method-of-use patents tied to insomnia dosing regimens.
- Formulation or solid-state patents (e.g., specific tablet characteristics and manufacturing controls).
- Exclusivity extensions from new clinical data and label expansion (where applicable).
What does exclusivity mean for generics and biosimilar-like competition?
Daridorexant is a small molecule, so “biosimilar risk” is not relevant. The competitive threat profile is generic entry under Abbreviated New Drug Applications after expiration of relevant exclusivities and patent rights, plus potential Paragraph IV challenges.
What patents protect daridorexant and what is the practical patent estate strength?
A defensible patent-estate view requires Orange Book listings and published patent families tied to the approved NDA. Without those filings and exact listing identifiers, precision on specific patent numbers and expirations cannot be produced.
What is the Orange Book status of QUVIVIQ (daridorexant)?
Orange Book status drives:
- Expiration-driven generic entry windows.
- Likely Paragraph IV aggressiveness.
- Settlement dynamics if generics file.
Without the exact Orange Book entries and listing identifiers, a complete status report cannot be stated.
How many Paragraph IV challenges could affect QUVIVIQ generic entry risk?
Insomnia is a crowded category where generic challengers often target the earliest legally permitted launch date. The number of potential Paragraph IV filings typically correlates with:
- Patent list depth in Orange Book.
- Litigation history with similar agents.
- Attractiveness of branded revenue and payer acceptance.
A quantified Paragraph IV outlook requires:
- Confirmed FDA approval dates and patent expiration dates in the Orange Book.
- History of prior ANDA filings for daridorexant.
Those data are not provided here, so no complete risk count can be produced.
What patent litigation affects QUVIVIQ commercialization timelines?
Litigation can delay generic launches via automatic stays or settlement entry dates.
A litigation status section requires:
- Docket-level case lists (district court, appellate posture).
- Settlement terms and agreed entry dates.
- Status of stays and whether generics remain enjoined.
Those specifics cannot be compiled accurately without case identifiers and filed documents.
What formulation and manufacturing IP barriers protect QUVIVIQ?
Small-molecule tablets often have multiple layers of IP:
- Composition and crystalline forms (if applicable).
- Tablet formulation (excipients, disintegration, dissolution profiles).
- Process controls (granulation, drying, compression).
- Stability and packaging specifications.
A detailed barrier map requires the exact patent families that reference the marketed dosage form and manufacturing steps. Without those exact identifiers, the barrier assessment cannot be completed.
What market size and sales projection scenarios apply to QUVIVIQ through 2030?
Projection methodology:
- Top-down: insomnia diagnosed populations, treated segment penetration, and branded share in insomnia pharmacotherapy.
- Bottom-up: addressable patients for QUVIVIQ-specific label fit, then expected share changes versus competitors by formulary tier and coverage design.
Scenario framework (directional, decision-useful)
- Base case: continued formulary retention with modest share gain from incremental physician adoption; sales grow slower as competitive orexin and non-orexin options saturate.
- Upside case: successful label-supporting trial readouts that broaden patient fit and strengthen payer value, driving tier shifts and reduced prior authorization friction.
- Downside case: payer preferencing against a competitor orexin agent or stronger negative perceptions about next-day impairment in specific subgroups, leading to share erosion and tighter utilization management.
What KPIs to monitor to validate the projection
- Prescriptions per week and new prescriber starts.
- PBM tier changes and prior authorization rates.
- Share of prescriptions within insomnia, split by class.
- Discontinuation or persistence rates at 30/90 days.
How does QUVIVIQ compare with insomnia competitors in commercial penetration and payer access?
Commercial penetration hinges on coverage:
- Step therapy requirements.
- Prior authorization criteria (e.g., failure of melatonin receptor agonists or short-acting sedatives).
- Quantity limits and switching policies.
- Preferred drug lists by health plan type.
A competitor-by-competitor comparison requires detailed formulary and claims datasets that are not included here, so only a framework can be stated.
Which commercial risks matter most for daridorexant and QUVIVIQ?
Top risk vectors that typically shift quarterly outcomes:
- Competitive preference: orexin class rivals can displace depending on formulary economics.
- Safety labeling effects: any new CNS safety guidance changes prescribing comfort.
- Patient adherence: insomnia therapies depend on consistent nightly use and tolerability.
- Generic/regulatory timing: even before generic entry, uncertainty around patent cliffs can reduce formulary commitments.
Key Takeaways
- QUVIVIQ’s commercial trajectory is driven by insomnia-specific evidence that supports durable efficacy, safe use in broader patient segments, and payer value.
- Near-term share will depend more on formulary dynamics and evidence packages than on mechanism alone, given the crowded insomnia landscape.
- Revenue downside risk concentrates around orexin-class competitive preference and any labeling or safety perception shifts.
- Patent and exclusivity timelines, Orange Book status, and litigation details determine generic entry risk, but those specifics cannot be stated without the underlying Orange Book and docketed data.
FAQs
1) What clinical endpoints most predict payer adoption for daridorexant in chronic insomnia?
Endpoints tied to sleep onset latency, WASO, responder rates, and next-morning impairment assessments drive value dossiers.
2) Does daridorexant have a different safety profile in older adults than Z-drugs?
Safety evaluation focuses on residual impairment signals, discontinuation, and TEAE CNS events, with age-stratified results shaping prescribing.
3) How do PBM step edits and prior authorization affect QUVIVIQ uptake?
They shift adoption from “covered instantly” to “requires documentation,” typically slowing new patient conversion and increasing initial prescription friction.
4) What would accelerate generic entry risk for QUVIVIQ?
Early expiration of the Orange Book patent list, successful Paragraph IV outcomes, and any settlement-triggered launch date.
5) What evidence would most likely expand daridorexant use beyond baseline insomnia?
Label-supporting results in broader insomnia phenotypes and comorbid patient populations with maintained tolerability and clinically meaningful sleep outcomes.
References (APA)
No sources were provided in the prompt, and no external source retrieval is available in this context.
